It may be as well to shift away from eponymous disease names but I don't see much logic in dropping apostrophes.
Couldn't agree more. I dropped the apostrophes through gritted teeth, but we decided as a group to go with it. Yes I had a little list to sometimes remind myself whether the apostrophe was before or after the 's' but I wanted to try and get that right in the same way I attempted to use the right plural or spelling (cough,
fetus).
I have mixed feelings on dropping eponymous names. I used to go to medical historical society meetings at one point and generally I appreciated propagating the medical history. Often knowing the story behind medical procedures (eg
Blalock-Thomas-Taussig shunt) helped cement ideas and also, at times, correct the historical record. Also, losing site of such history leads people to now wonder why was there that dip in global life-expectancy in 1958-60, just like the one we're seeing now, having
lost all sight of the Hong Kong flu pandemic.
Also, in training we all had to try and learn the various leukodystrophies (
Pelizaeus–Merzbacher,
Canavan,
Krabbe etc etc) in an attempt to be able to diagnose from the MRI distribution of white matter disease. We only needed to be able to do this from rote for around two weeks of part 2 exams. Afterwards of course, unless you're a subspecialist and seeing them every day, you simply look them up when necessary.
The eponymous names might be tricky to spell at times, but so would something like x-linked proteolipid-1 augmented hypomyelinating leukodystrophy. This would inevitably form an initialism, which is practically not much further ahead and likely harder to pronounce. Also some of these diseases have multiple causative gene defects, that are clinically irrelevant to sub-type in the absence of practical therapies, so you could end up with multiple pathology-based names for the same thing.
As for SARS, I still roll my eyes every time I read "severe acute severe acute respiratory syndrome" in texts (
1,
2,
3,
4). It's even in at least one title:
Decrease of Non-Classical and Intermediate Monocyte Subsets in Severe Acute SARS-CoV-2 Infection.